Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Studio Pictures Ltd is a UK-based film and TV production company founded by producers Adam Rolston and David Braithwaite in 2019. Specializing in creating high-quality British entertainment content, the company focuses on adapting books to screen and telling unique true-life stories that entertain and inspire both domestic and international audiences. With successful productions like "A Street Cat Named Bob," the company is building a strong brand and reputation in the industry. Studio Pictures has access to top creative talent and collaborates with major studios like Warner Bros, Sony Pictures, Lionsgate, and Studio Canal. The company is located at Twickenham Studios in Richmond, UK.
days to go:
24
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
CoachScanner connects companies and people looking for coach or minibus hire with local reliable operators. Since launching in March 2016 bookings are taking place with over 800 active Operators and the size of the industry in the UK has reached £2.7 billion.
days to go:
Expired
investment:
£79,090
Riversimple is a vehicle manufacturer and assistance provider exploring ‘next-generation’ electric vehicles. It offers its customers the first inexpensive, fun-to-drive and easy eco-car, delivered with a complete and cost-transparent subscription service. Riversimple has gained an investor base of over 950 shareholders from 21 countries including NZ, Japan, India and many more. The company has already raised over £2M, and its next step is to grow the engineering team and boost the volume of production engineering to enable it to reach commercialisation by 2021.
days to go:
Expired
investment:
£839,958
Clinical Net is a health-tech firm focused on revolutionizing access to innovative clinical trials. Their AI platform swiftly connects patients with suitable trials, addressing the challenge of low participation rates and delays that hinder pharmaceutical research. With over 69,000 trials globally, their solution aims to streamline the cumbersome and time-consuming process of trial matching, making it more efficient and accessible within 5 minutes. This innovative approach targets the $3.73 billion patient recruitment market while ensuring individuals have easier access to groundbreaking treatments.
days to go:
Expired
investment:
£136,827
Evaclite manufactures dynamic exit signs designed to make buildings safer and save lives. The company argues that its products are 77% more visible than conventional exit signs and reduces congestion at exits by 36%. The company received the 2018 FIREX - Fire Innovation of the Year Award. It also won the Safety and Health Excellence (SHE) Award in 2019 and 2020. Evaclite counts companies like Apple, CBRE, BBC, Melia, and MetroBank amongst its clients. The company has inquiries from over a dozen countries globally with a 12-month sales opportunity pipeline of over £1.5 million. It will use 60% of the investment to build its sales team, 28% to boost its inbound marketing campaign, 7% to develop additional intellectual property, and 5% towards overhead and general costs.
days to go:
Expired
investment:
£148,736
MGN Builders Merchants is a well-established, profitable, and a fast-growing builders merchants and skip hire based in London and Essex. It offers same or next day delivery on thousands of building products kept in stock at all times. Having served 50,000+ customers in 2018 (81k EBITDA), the company's client base includes small to medium-sized companies, private developers and DIY customers. In the last three years, the company has trebled its revenue from £2.5m in 2016 to £7m by January 2019, achieving an almost 100% sales increase YoY. MGN is raising funding to accelerate its rapid growth plans, expand its team, start selling online, and launch concrete delivery service to capture UK's £34bn construction supplied wholesale market.
days to go:
Expired
investment:
£114,260
Her.9 is a Direct-To-Consumer (DTC) female technology brand that caters to the needs of women during pregnancy. It cites research arguing that up to 40% of women taking prenatal vitamins may not be able to absorb the folic acid within the UK’s leading pregnancy brand. Her.9 aims to resolve this by employing DUOCAP technology. The company asserts that DUOCAP is a capsule-in-capsule delivery system which contains solubilised prebiotics in the outer capsule and probiotics in the inner capsule. The prebiotic releases immediately and the probiotic releases later allowing for targeted supplement delivery in the body. The prenatal supplements market is set to be worth $56 billion globally by 2024. Her.9 aims to be a notable contender in this segment. The company is raising investment to build its already established partnerships and execute its marketing strategy effectively.
days to go:
Expired
investment:
£215,946
